Satellite Symposia

Hear directly from industry in these popular one-hour virtual presentations. Pre-registration is not required, but encouraged to receive any pre-meeting materials from the organizing company. Note: CE Credits not offered for these Satellite Symposia.

Friday, June 11

3:45–4:45 pm EDT

True Digital SPECT/CT: Precision Imaging at the Speed of Tomorrow 
Sponsored by GE Healthcare


  • Dr. Barry Siegel | Professor of Radiology & Medicine; Washington School of Medicine, St Louis Matthieu Bailly | Head of the Nuclear Medicine Department, NM Physician, Hospital of Orleans, France
  • Andrei Iagaru, MD | Professor at Stanford University
  • Nick Karabatsos | Event Host & General Manager for Molecular Imaging at GE Healthcare, US & Canada

Please join us as innovative Molecular Imaging clinicians, each with many years of experience with CZT, share their insights on the current and potential impact of true digital SPECT/CT. They will discuss CZT technology and ongoing commitments to the advancement of Nuclear Medicine, including the introduction of and initial clinical experiences with a novel new digital SPECT/CT.

Utilizing Clinical Clues and Diagnostic Approaches to Identify Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Sponsored by Pfizer


  • Diwakar Jain MD, FACC, FRCP, FSNMMI, MASNC, Professor of Medicine at New York Medical College, Director of Nuclear Cardiology, Director of Cardio-Oncology Program, Westchester Medical Center, Valhalla, NY 

Transthyretin amyloid cardiomyopathy (or ATTR-CM) is an underrecognized and underdiagnosed disease that frequently presents as heart failure. This presentation will provide an overview of ATTR-CM and highlight how to recognize the signs and symptoms that raise suspicion of ATTR-CM, while introducing approaches to achieve a differential diagnosis—with a focus on nuclear scintigraphy. The program will end with a review of the clinical data for a treatment option for ATTR-CM.

5:00-6:00 pm EDT

Theranostics and the Future: How to Prepare for these Novel Radiopharmaceuticals
Sponsored by Cardinal Health


  • Kathi Benson, RPH, ANP, Director, Nuclear & Precision Health Solutions, Cardinal Health
  • Luke Augustine, PharmD, BCNP, Vice President, Business Development, Nuclear & Precision Health Solutions, Cardinal Health

This session will explore current industry trends and examine how theranostics plays a critical role in the future of nuclear medicine. Attendees will also learn about steps they can take to prepare for these therapies.

Advancing the Clinical Frontiers of Ultra-high-resolution Digital PET
Sponsored by United Imaging


  • David M. Schuster MD, FACR, Professor, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Director, Division of Nuclear Medicine and Molecular Imaging, Emory University School of Medicine
  • Simon R. Cherry, PhD,Co-Director, EXPLORER Molecular Imaging Center, Distinguished Professor of Biomedical Engineering and Department of Radiology, UC Davis Health 
  • Dr. Lorenzo Nardo, MD, PhD, Associate Professor, Department of Radiology, UC Davis Health
  • K. Lance Gould, MD, Distinguished University Chair in Cardiovascular Medicine at The University of Texas Health Science Center at Houston (UTHealth)

In this session the panel will discuss the cutting-edge clinical and research impacts of ultra-high-resolution digital PET that are advancing the paradigms of molecular imaging. You will learn about the: 

  • Most recent clinical and research impacts of total-body PET  
  • Clinical use of high-resolution digital cardiac PET with Rb-82  
  • Impact of PET AI reconstruction in routine PET imaging 
  • This session will include an interactive Q&A.

Saturday, June 12

10:30–11:30 am EDT

Neurology and Nuclear Medicine: Working Together for an Optimal Dementia Diagnosis

Sponsored by GE Healthcare


  • Gill Farrar, PhD, Global Medical Director, Neurology, GE Healthcare


  • Prof. Valentina Garibotto, MD, Geneva University and Geneva University Hospital, Division of Nuclear Medicine and Molecular Imaging 
  • Prof. Giovanni Frisoni, MD, Geneva University and Geneva University Hospital, Division of Neurology, Head of the Outpatient Memory Center 

Hear how Professors Giovanni Frisoni and Valentina Garibotto work closely together to link the Neurology and Nuclear Medicine Departments to provide an optimal diagnosis for their dementia patients. This session will explore interesting cases taken from the AMYPAD (European amyloid PET consortium) Diagnostic and Patient Management Study and highlight the value of the close working relationship between these two departments.

Cardiac PET: Practical Considerations in Starting a Program
Sponsored by Jubilant Radiopharma


  •  Rupa M Sanghani, MD, FACC, FASNC, Associate Professor of Medicine, Director of Nuclear Cardiology and Stress Laboratory, Rush University Medical Center


  • Practical issues to consider before starting a cardiac PET program (financial and design)
  • Hardware and Software considerations for Cardiac PET.
  • How to train your staff when beginning cardiac PET.

11:45 am–12:45 pm EDT

The Role of PET in Post-Prostatectomy Radiotherapy
Sponsored by Blue Earth Diagnostics, a Bracco Company


  •  Ashesh Jani, MD, MSEE, FASTRO, James C. Kennedy Professor, Department of Radiation Oncology, Winship Cancer Institute of Emory University

 In this session the clinical need for molecular imaging for recurrent prostate cancer will be reviewed, with particular emphasis on the post-prostatectomy radiotherapy setting. The role of PET imaging in guiding management decisions and influencing treatment outcomes will be reviewed, including sample case scenarios. The design and results of the EMPIRE-1 randomized trial will be reviewed, and future directions of the role of PET in prostate cancer will be discussed. No CE credits will be provided.

   Technegas® …. A new era in Nuclear Pulmonology
   Sponsored by Cyclomedica


  • Professor Norman Laurin : Nuclear medicine specialist, Nuclear medicine service, CIUSSS-MCQ and Centre Hospitalier Affilié Universitaire Régional, Trois-Rivières, Québec, Canada
  • Dr Elizabeth Bailey : Chief Nuclear Medicine Technologist, Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia
  • Dr Geoff Currie: Professor in Nuclear Medicine, Charles Sturt University, Wagga Wagga, Australia
  • Pr Greg King: Respiratory physician, Department of Respiratory Medicine, Royal North Shore Hospital, University of Sydney, Sydney, Australia

This session will explore functional lung ventilation imaging in the diagnosis of 
Pulmonary Embolism (PE) and potential new Beyond PE clinical applications. Attendees will learn how to take advantage of advanced technologies to unlock a new era in Nuclear Pulmonology.

Sunday, June 13

12:45–1:45 pm EDT

Maximizing the Clinical Impact of Receptor Imaging in Breast Cancer

Sponsored by PETNET Solutions


  •  Deepak Behera, MD, Medical Imaging Consultancy


  • David Mankoff, MD, PhD, Gerd Muehllehner Professor of Radiology, University of Pennsylvania
  • Amy Clark, MD, MSCE, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
  • Jeremy Force, DO, Medical Oncologist, Duke Health

Novel receptor imaging agents address questions about improving care standards for breast cancer patients. PETNET Solutions, Inc. presents a panel discussion exploring how to identify the right patient, what to do with the information once you get it, and where heterogeneity comes into play.

PSMA-PET/CT: Integrating Imaging with the Care Team
Sponsored by Telix Pharmaceuticals


  •  Colin Hayward, MBBS FFPM, CMO Telix Pharmaceuticals


  • Daniel W. Lin, MD | Professor and Chief of Urologic Oncology; Pritt Family Endowed Chair in Prostate Cancer Research; Director, Institute for Prostate Cancer Research (IPCR); Department of Urology, University of Washington
  • Delphine L. Chen, M.D. | Professor of Radiology; Wil B. Nelp, M.D. Endowed Professorship in Nuclear Medicine; Director of Molecular Imaging, Seattle Cancer Care Alliance; Department of Radiology, University of Washington
  • Preston C. Sprenkle, MD | Associate Professor of Urology; Division Chief, Division of Urology at VA Connecticut Healthcare System; Director, Urology; Research Fellowship; Director, Urologic Oncology Clinical Fellowship Program; Yale School of Medicine
  • Darko Pucar, MD, PhD | Co-director of Molecular Imaging Clinical and Translational Research Laboratory (MICTRL); Yale Medicine

Program Summary: The goal of this program is to achieve maximum impact of improved patient care by addressing the fact that members of the patient management team have specific clinical questions that need answering in order to properly treat Prostate cancer. The impact in patient care and outcomes is improved if the clinical answers accurately guide the patient’s journey. 

The Overall Goals:

  • Review the needs of the care team members in order to deliver clear and concise PSMA PET/CT reports to facilitate prostate cancer management.
  • Explain why Urologists and Radiation Oncologists need an accurate description of all sites of local, regional, and metastatic prostate cancer to optimize treatment planning and oncologic outcomes.
  • Explain why Medical Oncologists need accurate information from PSMA PET/CT for staging, restaging, and treatment response assessment of prostate cancer.
  • Optimize the communication between the members of the patient management team.
  • Develop standardized guidelines for PSMA PET/CT reporting to optimize intra- and inter-institutional clinical care and research, including multi-institutional clinical trials. 

Monday, June 14

12:45–1:45 pm EDT

PET Imaging in Potentially Evolving Treatment Paradigms for Alzheimer’s Disease

Sponsored by Biogen


  • Ana Franceschi, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, NY, USA 
  • Paul Schulz, McGovern Medical School of UTHealth, Houston, TX, USA
  • Tammie Benzinger, Washington University School of Medicine, St. Louis, MO, USA

Please join our eminent faculty in this Biogen-sponsored symposium, in which we will discuss the considerations for the role of positron emission tomography (PET) imaging in evolving treatment paradigms for Alzheimer’s disease. We will present an overview of Alzheimer’s disease before providing an update on developments in amyloid and tau PET imaging. A review of PET imaging data from clinical trials will be presented, followed by a panel discussion of several patient case studies that will examine the use of PET imaging to confirm an Alzheimer’s disease diagnosis. There will also be an opportunity to ask your questions in a live Q&A.

Practical Applications and Clinical Utility of an 18F PSMA-Targeted PET Imaging Agent: Implications for Urology and Radiation Oncology
Sponsored by Lantheus


  • Phillip Koo, MD, Chief of Diagnostic Imaging and Oncology Physician Executive, Banner MD Anderson Cancer Center
  • E. David Crawford, MD, Professor of Urology, University of California, San Diego, Editor and Chief, Grand Rounds in Urology
  • Steven E. Finkelstein, MD, DABR, FACRO, Radiation Oncologist, Florida Cancer Affiliates/US Oncology Network

In this session, the panel will discuss the research and clinical implications of an 18F PSMA-targeted prostate imaging biomarker. This session will include Q &A. You will learn about:

  • The current and future role of prostate-specific membrane antigen (PSMA) PET/CT in the management of prostate cancer
  • Clinical data and results from the OSPREY and CONDOR pivotal studies

Tuesday, June 15

12:45–1:45 pm EDT

Novartis’ Commitment to Targeted Radioligands in Oncology
Sponsored by Advanced Accelerator Applications, A Novartis Company


  •  Stephen Moran, PhD, Global Program Head, Global Drug-Development, Advanced Accelerator Applications, a Novartis company

Updates on Novartis’ commitment to research in targeted radioligands and the scientific rationale for patients with cancer

Biograph Vision Quadra First Impressions – A quantum leap in PET/CT imaging
Sponsored by Siemens Healthineers


  •  Prof. Dr. Med. Axel Rominger, Director of the Department of Nuclear Medicine, Insel Gruppe AG
  • Katherina Swystun, Global PET/CT Product Marketing Manager, Siemens Healthineers Molecular Imaging

During this event, Prof. Axel Rominger, the director of the department of nuclear medicine at Switzerland’s Inselspital, Bern University Hospital, will share his first impressions and experiences, as the first worldwide user of the next generation whole-body PET/CT scanner, Biograph Vision Quadra1. Additionally, we will highlight how Biograph Vision Quadra combines the best of both worlds: an extended axial PET field of view (FoV) with industry-leading detector technology, to expand the boundaries of research and reshaped clinical outcomes.

1 Biograph Vision Quadra is not commercially available in all countries. Its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.